Retractable Technologies, Inc. (NYSE American: RVP) reported total net sales of $14.1 million for the third quarter of 2026, a 39.6% increase compared to the $10.1 million reported for the same period in 2025. The company recorded an operating loss of $4.1 million for the third quarter of 2026, compared to an operating loss of $3.7 million in the prior year. For the first nine months of 2026, net sales totaled $28.5 million, with an operating loss of $15.5 million. This compares to 2025 net revenues of $28.8 million and operating losses of $13.5 million.

Domestic net sales accounted for 90.3% of total net sales in the third quarter of 2026, representing a 38.9% increase year-over-year. This growth was driven by a 59.5% increase in domestic unit sales, largely due to the timing of EasyPoint® product orders. The company noted that a shift in product mix toward EasyPoint® needles, which traditionally carry a lower average selling price than syringes, contributed to the difference between the growth in unit sales and net sales. International net sales increased by 52.2% in the third quarter, primarily driven by increased EasyPoint® needle sales.

The company attributes the increase in operating losses to lower gross margins, resulting from changes in the domestic and international product sales mix. However, operating expenses decreased by 18.9% in the third quarter, primarily due to lower gross wages in the Sales and Marketing department and reduced donation and credit loss expenses in General and administrative expenses. Retractable also noted that cost of manufactured product increased by 69.9% due to higher unit volumes.

Regarding tariffs, Retractable spent approximately $260,000 on tariff expenses in the third quarter of 2026. The company continues to mitigate these costs through strategic sourcing decisions and increased domestic production, which comprised 40.3% of units manufactured during the first nine months of 2026. Additionally, a reduction in force in April 2026 resulted in cost savings. The company reported a net loss of $2.4 million for the three months ended September 30, 2026, and a net loss of $3.8 million for the nine-month period. This included a $6.4 million gain on the sale of equity securities during the nine-month period.